Kamen and Sequel Medtech CEO Alan Lotvin say they are offering greater precision in insulin delivery with new pump technology ...

Insulet saw strong insulin pump adoption among new users with Type 2 diabetes following its recent FDA clearance, while ...

The company now expects its annual 2024 revenue to grow between 20% and 21%, up from its previous forecast of 16% to 19% ...

Nov 7(Reuters) - Insulet (PODD.O), opens new tab raised its annual revenue growth forecast on Thursday, banking on strong demand for its wearable insulin pumps. Shares of the medical device maker ...

Q3 2024 Earnings Call Transcript November 6, 2024 Tandem Diabetes Care, Inc. beats earnings expectations. Reported EPS is $-0 ...

Analyst Jeff Johnson from Robert W. Baird maintained a Buy rating on Insulet (PODD – Research Report) and keeping the price target at ...

1 mylife Loop consists of the mylife YpsoPump, a lightweight intuitive insulin pump, integrated with the CamAPS FX hybrid ...

Insulet’s management has shown strategic foresight by increasing their outreach to primary care providers, aiming to capitalize on the underpenetrated insulin pump market. This, coupled with the ...

SAN DIEGO, CA / ACCESSWIRE / November 11, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump ...

Tandem Diabetes Care shares ticked up after hours today on third-quarter results that topped the consensus forecast.

PLYMOUTH MEETING, Pa. – AdaptHealth CEO Suzanne Foster is doubling down on efforts to turn around the company’s struggling diabetes business, saying it was “worse” than she initially thought it was.